Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
Australia's Therapeutic Goods Administration has issued a warning linking GLP-1 weight loss and diabetes drugs, such as Ozempic and Mounjaro, to a rare but severe eye disorder called NAION. Patients are advised to seek medical attention for sudden vision loss but not to stop treatment without consulting a doctor.
Why it matters
This warning provides critical safety information for a large population of patients using popular weight-loss and diabetes medications.
The Therapeutic Goods Administration warning came after several GLP-1 RA medicines marketed in Australia as Ozempic, Wegovy and Mounjaro, among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. Photograph: James Manning/PA The Therapeutic Goods Administration warning came after several GLP-1 RA medicines marketed in Australia as Ozempic, Wegovy and Mounjaro, among other products, were linked to 36 cases of the eye disorder, non-arteritic anterior ischaemic optic neuropathy. Photograph: James Manning/PA Health Australian regulator warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder
Follow our Australia news live blog for latest updates
Get our breaking news email , free app or daily news podcast
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in